Epidemiology of cognitive aging and alzheimer’s disease: Contributions of the cache county utah study of memory, health and aging

Current Topics in Behavioral Neurosciences

Volumn 10, Issue , 2011, Pages 3-31

  Hayden, Kathleen M ^a   Welsh Bohmer, Kathleen A ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer s disease; Epidemiology; Mildcognitive impairment; Population based study; Prodromal AD

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; APOLIPOPROTEIN E; ASCORBIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; VITAMIN;

ALZHEIMER DISEASE; ARTICLE; COGNITIVE AGING; COGNITIVE DEFECT; DEMENTIA; DIAGNOSTIC ACCURACY; EPISODIC MEMORY; EXECUTIVE FUNCTION; GEOGRAPHIC DISTRIBUTION; HORMONE SUBSTITUTION; HUMAN; LIFESTYLE; MEMORY; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; NONHUMAN; PHARMACOGENETICS; PREDICTIVE VALUE; PRIORITY JOURNAL; SCORING SYSTEM; WORD RECOGNITION; AGING; COGNITION DISORDERS; DEMOGRAPHY; DISEASE COURSE; EPIDEMIOLOGY; FEMALE; INCIDENCE; LONGITUDINAL STUDY; MALE; MEMORY DISORDERS; PATHOPHYSIOLOGY; PREVALENCE; PRODROMAL SYMPTOM; PSYCHOLOGY; RISK FACTOR; UNITED STATES;

AGING; ALZHEIMER DISEASE; COGNITION DISORDERS; DISEASE PROGRESSION; FEMALE; HUMANS; INCIDENCE; LIFE STYLE; LONGITUDINAL STUDIES; MALE; MEMORY DISORDERS; NEUROPSYCHOLOGICAL TESTS; PREVALENCE; PRODROMAL SYMPTOMS; RESIDENCE CHARACTERISTICS; RISK FACTORS; UTAH;

EID: 84886729242     PISSN: 18663370     EISSN: 18663389     Source Type: Book Series    
DOI: 10.1007/7854_2011_152     Document Type: Article

References (121)

1. Aisen PS, Schafer KA et al (2003) Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. J Am Med Assoc 289(21): 2819-2826
2. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd edn revised: DSM-III-R. American Psychiatric Association, Washington
3. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn: DSM-IV. American Psychiatric Association, Washington
4. Andersen K, Launer LJ et al (1995) Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 45(8): 1441-1445
5. Backman L, Jones S et al (2005) Cognitive impairment in preclinical Alzheimer's disease: a meta-analysis. Neuropsychology 19(4): 520-531
6. Baker LD, Frank LL et al (2010) Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch Neurol 67(1): 71-79
7. Barnes LL, Mendes de Leon CF et al (2004) Social resources and cognitive decline in a population of older African Americans and Whites. Neurology 63(12): 2322-2326
8. Beck AT, Steer RA et al (1996) Manual for the beck depression inventory-II. Psychological Corporation, San Antonio
9. Benton A (1992) Benton Visual Retention Test, 5th edn. Psychological Corporation, New York
10. Benton AL, Hamsher K (eds) (1983) Multilingual aphasia examination. AJA Associates, Iowa City
11. Blackford RC, LA Rua A (1989) Criterion for diagnosing age associated memory impairment: proposed improvements from the field. Dev Neuropsychol 5: 298-300
12. Bozoki A, Giordani B et al (2001) Mild cognitive impairments predict dementia in nondemented elderly patients with memory loss. Arch Neurol 58(3): 411-416
13. Braak H, Braak E (1996) Evolution of the neuropathology of Alzheimer's disease. Acta Neurol Scand Suppl 165: 3-12
14. Brayne C, Stephan BC et al (2011) A European perspective on population studies of dementia. Alzheimers Dement 7(1): 3-9
15. Breitner JC, Gau BA et al (1994a) Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 44(2): 227-232
16. Breitner JC, Welsh KA et al (1994b) Alzheimer's disease in the NAS-NRC registry of aging twin veterans. II. Longitudinal findings in a pilot series. National Academy of Sciences. National Research Council Registry. Dementia 5(2): 99-105
17. Breitner JC, Welsh KA et al (1995) Alzheimer's disease in the National Academy of Sciences-National Research Council Registry of Aging Twin Veterans. III. Detection of cases, longitudinal results, and observations on twin concordance. Arch Neurol 52(8): 763-771
18. Breitner JC, Wyse BW et al (1999) APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. Neurology 53(2): 321-331
19. Breteler MM, Claus JJ et al (1992) Epidemiology of Alzheimer's disease. Epidemiol Rev 14: 59-82
20. Brookmeyer R, Johnson E et al (2007) Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3(3): 186-191
21. Brookmeyer R, Evans DA et al (2011) National estimates of the prevalence of Alzheimer's disease in the United States. Alzheimers Dement 7(1): 61-73
22. Carlson MC, Zandi PP et al (2001) Hormone replacement therapy and reduced cognitive decline in older women: the Cache County Study. Neurology 57(12): 2210-2216
23. Carlson MC, Erickson KI et al (2009) Evidence for neurocognitive plasticity in at-risk older adults: the experience corps program. J Gerontol A Biol Sci Med Sci 64(12): 1275-1282
24. Corder EH, Saunders AM et al (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261(5123): 921-923
25. Crook T, Bartus RT et al (1986) Age-associated memory impairment: proposed diagnostic criteria and measures of clinical change-report of a National Institute of Mental Health Work Group. Dev Neuropsychol 2(4): 261-276
26. Cummings JL, Mega M et al (1994) The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44(12): 2308-2314
27. DeKosky ST, Carrillo MC et al (2011) Revision of the criteria for Alzheimer's disease: a symposium. Alzheimers Dement 7(1): e1-e12
28. Dubois B, Feldman HH et al (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6(8): 734-746
29. Folstein MF, Folstein SE et al (1975) ''Mini-mental state''. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3): 189-198
30. Fotuhi M, Zandi PP et al (2006) APOE ε4 positive elderly taking anti-oxidant vitamins E and C in combination with NSAIDs develop less cognitive decline with aging: the Cache County Study. In: 10th international conference on Alzheimer's disease and related disorders, Madrid, Spain
31. Goldman W, Price J et al (2001) Absence of cognitive impairment or decline in preclinical Alzheimer's disease. Neurology 56(3): 361-367
32. Graham JE, Rockwood K et al (1997) Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 349(9068): 1793-1796
33. Hayden KM, Warren LH et al (2005) Identification of VaD and AD prodromes: the Cache County Study. Alzheimers Dement 1(1): 19-29
34. Hayden KM, Zandi PP et al (2006) Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County Study. Alzheimer Dis Assoc Disord 20(2): 93-100
35. Hayden KM, Zandi PP et al (2007) Does NSAID use modify cognitive trajectories in the elderly? The Cache County Study. Neurology 69(3): 275-282
36. Heart Protection Study Collaborative Group (1999) MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 20(10): 725-741
37. Hebert LE, Scherr PA et al (2003) Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 60(8): 1119-1122
38. Hofman A, Ott A et al (1997) Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349(9046): 151-154
39. Honig LS, Tang MX et al (2003) Stroke and the risk of Alzheimer disease. Arch Neurol 60(12): 1707-1712
40. in 't Veld BA, Launer LJ et al (1998) NSAIDs and incident Alzheimer's disease. The Rotterdam Study. Neurobiol Aging 19(6): 607-611
41. Jorm AF, Jacomb PA (1989) The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychol Med 19(4): 1015-1022
42. Jorm AF, Jolley D (1998) The incidence of dementia: a meta-analysis. Neurology 51(3): 728-733
43. Jorm AF, Korten AE et al (1987) The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 76(5): 465-479
44. Kaplan E, Goodglass H et al (1978) The Boston naming test. Veterans Administration, Boston
45. Katzman R (1976) Editorial: the prevalence and malignancy of Alzheimer disease. A major killer. Arch Neurol 33(4): 217-218
46. Kawas C, Segal J et al (1994) A validation study of the Dementia Questionnaire. Arch Neurol 51(9): 901-906
47. Khachaturian AS, Zandi PP et al (2006) Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol 63(5): 686-692
48. Kivipelto M, Helkala EL et al (2001) Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology 56(12): 1683-1689
49. Kryscio RJ, Mendiondo MS et al (2004) Designing a large prevention trial: statistical issues. Stat Med 23(2): 285-296
50. Langa KM, Plassman BL et al (2005) The aging, demographics, and memory study: study design and methods. Neuroepidemiology 25(4): 181-191
51. Launer LJ (2011) Counting dementia: there is no one ''best'' way. Alzheimers Dement 7(1): 10-14
52. Launer LJ, Brock DB (2004) Population-based studies of AD: message and methods: an epidemiologic view. Stat Med 23(2): 191-197
53. Launer LJ, Ross GW et al (2000) Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 21(1): 49-55
54. Lautenschlager NT, Cox KL et al (2008) Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. J Am Med Assoc 300(9): 1027-1037
55. Levy R (1994) Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization. Int Psychogeriatr 6(1): 63-68
56. Lindsay J, Sykes E et al (2004) More than the epidemiology of Alzheimer's disease: contributions of the Canadian Study of Health and Aging. Can J Psychiatry 49(2): 83-91
57. Luchsinger JA, Tang MX et al (2003) Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 60(2): 203-208
58. Lyketsos CG, Toone L et al (2006) A population-based study of the association between coronary artery bypass graft surgery (CABG) and cognitive decline: the Cache County Study. Int J Geriatr Psychiatry 21(6): 509-518
59. Manly JJ, Bell-McGinty S et al (2005) Implementing diagnostic criteria and estimating frequency of mild cognitive impairment in an urban community. Arch Neurol 62(11): 1739-1746
60. Manton KG, Tolley HD (1991) Rectangularization of the survival curve: implications of an illposed question. J Aging Health 3(2): 172-193
61. Martin BK, Szekely C et al (2008) Cognitive function over time in the Alzheimer's Disease Antiinflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 65(7): 896-905
62. Mayeux R, Reitz C et al (2011) Operationalizing diagnostic criteria for Alzheimer's disease and other age-related cognitive impairment-part 1. Alzheimers Dement 7(1): 15-34
63. McGeer PL, Schulzer M et al (1996) Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47(2): 425-432
64. McGinnis JM, Foege WH (1993) Actual causes of death in the United States. J Am Med Assoc 270(18): 2207-2212
65. McKhann G, Drachman D et al (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34(7): 939-944
66. Meinert CL, Breitner JC (2008) Chronic disease long-term drug prevention trials: lessons from the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimers Dement 4(Suppl 1): S7-S14
67. Miech RA, Breitner JC et al (2002) Incidence of AD may decline in the early 90s for men, later for women: the Cache County Study. Neurology 58(2): 209-218
68. Mielke MM, Rosenberg PB et al (2007) Vascular factors predict rate of progression in Alzheimer disease. Neurology 69(19): 1850-1858
69. Morris MC, Beckett LA et al (1998) Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Dis Assoc Disord 12(3): 121-126
70. Morris JC, Storandt M et al (2001) Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 58(3): 397-405
71. Murray CJL, Michaud CM et al (1988) U. S. patterns of mortality by county and race: 1965-1994. C. f. P. a. D. Studies. Harvard, Cambridge
72. Norton MC, Breitner JC et al (1994) Characteristics of nonresponders in a community survey of the elderly. J Am Geriatr Soc 42(12): 1252-1256
73. Ostbye T, Krause KM et al (2006) Ten dimensions of health and their relationships with overall self-reported health and survival in a predominately religiously active elderly population: the Cache County Memory Study. J Am Geriatr Soc 54(2): 199-209
74. Ott A, Breteler MM et al (1997) Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 28(2): 316-321
75. Ott A, Stolk RP et al (1999) Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 53(9): 1937-1942
76. Paleologos M, Cumming RG et al (1998) Cohort study of vitamin C intake and cognitive impairment. Am J Epidemiol 148(1): 45-50
77. Park DC, Reuter-Lorenz P (2009) The adaptive brain: aging and neurocognitive scaffolding. Annu Rev Psychol 60: 173-196
78. Petersen RC, Morris JC (2005) Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol 62(7): 1160-1163, discussion 1167
79. Petersen RC, Smith GE et al (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56(3): 303-308
80. Plassman BL, Langa KM et al (2007) Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 29(1-2): 125-132
81. Plassman BL, Langa KM et al (2008) Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med 148(6): 427-434
82. Plassman BL, Williams JW Jr et al (2010) Systematic review: factors associated with risk for and possible prevention of cognitive decline in later life. Ann Intern Med 153(3): 182-193
83. Plassman BL, Langa KM et al (2011) Incidence of dementia and cognitive impairment, not dementia in the United States. Ann Neurol [Epub ahead of print]
84. Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and ''preclinical'' Alzheimer's disease. Ann Neurol 45(3): 358-368
85. Price JL, Ko AI et al (2001) Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol 58(9): 1395-1402
86. Quinn JF, Montine KS et al (2004) Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease. J Alzheimers Dis 6(1): 93-97
87. Refolo LM, Malester B et al (2000) Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7(4): 321-331
88. Reitan R (1958) Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 8: 271-276
89. Rockwood K, Ebly E et al (1997) Presence and treatment of vascular risk factors in patients with vascular cognitive impairment. Arch Neurol 54(1): 33-39
90. Roman GC, Tatemichi TK et al (1993) Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43(2): 250-260
91. Sano M, Ernesto C et al (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336(17): 1216-1222
92. Scarmeas N, Stern Y et al (2006) Mediterranean diet and risk for Alzheimer's disease. Ann Neurol 59(6): 912-921
93. Scarmeas N, Luchsinger JA et al (2009) Physical activity, diet, and risk of Alzheimer disease. J Am Med Assoc 302(6): 627-637
94. ShipleyW (1967) Shipley Institute of Living Scale. Western Psychological Services, Los Angeles
95. Skoog I, Lernfelt B et al (1996) 15-year longitudinal study of blood pressure and dementia. Lancet 347(9009): 1141-1145
96. Sliwinski M, Buschke H et al (1997) The effect of dementia risk factors on comparative and diagnostic selective reminding norms. J Int Neuropsychol Soc 3(4): 317-326
97. Smith A (1991) Symbol Digit Modalities Test. Western Psychological Services, Los Angeles
98. Smith PJ, Blumenthal JA et al (2010) Aerobic exercise and neurocognitive performance: a metaanalytic review of randomized controlled trials. Psychosom Med 72(3): 239-252
99. Stewart WF, Kawas C et al (1997) Risk of Alzheimer's disease and duration of NSAID use. Neurology 48(3): 626-632
100. Strauss E, Sherman EMS, Spreen O (eds) (2006) A Compendium of Neuropsychological Tests, 3rd edn. Oxford University Press, New York
101. Treiber KA, Carlson MC et al (2011) Cognitive stimulation and cognitive and functional decline in Alzheimer's disease: the Cache County Dementia Progression Study. J Gerontol B Psychol Sci Soc Sci
102. Tschanz JT, Welsh-Bohmer KA et al (2000) Dementia diagnoses from clinical and neuropsychological data compared: the Cache County Study. Neurology 54(6): 1290-1296
103. Tschanz JT, Welsh-Bohmer KA et al (2002) An adaptation of the modified mini-mental state examination: analysis of demographic influences and normative data: the Cache County Study. Neuropsychiatry Neuropsychol Behav Neurol 15(1): 28-38
104. Tschanz JT, Treiber K et al (2005) A population study of Alzheimer's disease: findings from the Cache County Study on memory, health, and aging. Care Manag J 6(2): 107-114
105. Tschanz JT, Welsh-Bohmer KA et al (2006) Conversion to dementia from mild cognitive disorder: the Cache County Study. Neurology 67(2): 229-234
106. Tuokko HA, Frerichs RJ et al (2001) Cognitive impairment, no dementia: concepts and issues. Int Psychogeriatr 13(Supp 1): 183-202
107. Unverzagt FW, Smith DM et al (2009) The Indiana Alzheimer Disease Center's symposium on mild cognitive impairment. Cognitive training in older adults: lessons from the ACTIVE Study. Curr Alzheimer Res 6(4): 375-383
108. Wechsler D (1987) WMS-R: Wechsler Memory Scale-Revised. Harcourt Brace Jovanovich, New York
109. Wechsler D (1997) Wechsler Adult Intelligence Scales, 3rd edn. The Psychological Corporation, San Antonio
110. Weggen S, Eriksen JL et al (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414(6860): 212-216
111. Welsh KA, Butters N et al (1994) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology 44(4): 609-614
112. Welsh-Bohmer KA, Mohs RC (1997) Neuropsychological assessment of Alzheimer's disease. Neurology 49(Suppl 3): S11-13
113. Welsh-Bohmer KA, Ostbye T et al (2009) Neuropsychological performance in advanced age: influences of demographic factors and Apolipoprotein E: findings from the Cache County Memory Study. Clin Neuropsychol 23(1): 77-99
114. Wengreen HJ, Munger R et al (2005). Fruit and vegetable intake and cognitive function in the elderly: the Cache County Study on memory, health and aging. Alzheimer's Dementia J Alzheimer's Assoc 1(1): S100
115. Wengreen HJ, Munger RG et al (2007) Antioxidant intake and cognitive function of elderly men and women: the Cache County Study. J Nutr Health Aging 11(3): 230-237
116. Wengreen H, Munger R et al Prospective study of DASH-and Mediterranean-style dietary patterns and age-related cognitive change. J Nutr Health Aging (in press)
117. Whitmer RA, Quesenberry CP et al (2011) Timing of hormone therapy and dementia: the critical window theory revisited. Ann Neurol 69(1): 163-169
118. Wolinsky FD, Vander Weg MW et al (2010) Does cognitive training improve internal locus of control among older adults? J Gerontol B Psychol Sci Soc Sci 65(5): 591-598
119. Zandi PP, Anthony JC et al (2002a) Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 59(6): 880-886
120. Zandi PP, Carlson MC et al (2002b) Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. J Am Med Assoc 288(17): 2123-2129
121. Zandi PP, Anthony JC et al (2004) Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 61(1): 82-88